This discrepancy may be explained by two reasons: (i) polymorphism of ABCB1 and/or ABCG2 determined the clinical response to sorafenib in patients with HCC [98]; and (ii) expression of the ABC transporters was associated with the differentiation degree of the HCC. This evidence concerns the gene ABCG2 and hepatocellular carcinoma.